Search

Your search keyword '"Vittecoq, Olivier"' showing total 442 results
Start Over Author "Vittecoq, Olivier" Publication Type Academic Journals
442 results on '"Vittecoq, Olivier"'

1. Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts

Author

Nguyen, Yann, Nocturne, Gaëtane, Henry, Julien, Ng, Wan-Fai, Belkhir, Rakiba, Desmoulins, Frédéric, Bergé, Elisabeth, Morel, Jacques, Perdriger, Aleth, Dernis, Emmanuelle, Devauchelle-Pensec, Valérie, Sène, Damien, Dieudé, Philippe, Couderc, Marion, Fauchais, Anne-Laure, Larroche, Claire, Vittecoq, Olivier, Salliot, Carine, Hachulla, Eric, Le Guern, Véronique, Gottenberg, Jacques-Eric, Mariette, Xavier, and Seror, Raphaèle

Published
2024
Full Text
View/download PDF

4. The determinants associated with the prescription of a first biologic therapy in patients with axial spondyloarthritis and concomitant fibromyalgia are mostly objective and in line with the recommendations. Results of a cross-sectional survey-based study using a mixed (qualitative and quantitative) approach to help rheumatologists in their daily practice

Author

Renouprez, Thibaut, Gillibert, André, Gerard, Baptiste, Pouplin, Sophie, Marcelli, Christian, Lequerre, Thierry, Schuers, Matthieu, and Vittecoq, Olivier

Published
2024
Full Text
View/download PDF

7. Épidémiologie de l’atteinte dermatologique dans le syndrome de Sjögren : données provenant de trois populations françaises de Syndrome de Sjogren primitif (TEARS, ASSESS, diapSS)

Author

Villon, Camille, Orgeolet, Laure, Roguedas, Anne-Marie, Misery, Laurent, Gottenberg, Jacques-Eric, Cornec, Divi, Jousse-Joulin, Sandrine, Seror, Raphaele, Berthelot, Jean-Marie, Dieude, Philippe, Dubost, Jean-Jacques, Fauchais, Anne-Laure, Goeb, Vincent, Hachulla, Eric, Hatron, Pierre-Yves, Larroche, Claire, Hayem, Gilles, Le Guern, Véronique, Perdriger, Aleth, Morel, Jacques, Vittecoq, Olivier, Mariette, Xavier, Devauchelle-Pensec, Valérie, and Saraux, Alain

Published
2022
Full Text
View/download PDF

8. Impact of the Clinical Pharmacist in Rheumatology Practice: A Systematic Review.

Author

Barat, Eric, Soubieux, Annaelle, Brevet, Pauline, Gerard, Baptiste, Vittecoq, Olivier, Lequerre, Thierry, Chenailler, Catherine, Varin, Rémi, and Lattard, Claire

Subjects
PATIENT compliance, OCCUPATIONAL roles, MEDICATION errors, CINAHL database, PATIENT care, TREATMENT effectiveness, MEDICATION reconciliation, MEDLINE, MEDICAL databases, RHEUMATOLOGY, ONLINE information services, DRUGS, MEDICAL care costs
Abstract

This is a systematic literature review on the impact of pharmacists in rheumatology, conducted using the PubMed®, CINAHL®, Cochrane Library®, and Web of science® databases and using the PRISMA 2020 checklist. This review was conducted from 2000 to June 2024. A quality analysis was performed. The selection of articles, as well as all analyses, including quality analyses, were conducted by a pair of pharmacists with experience in rheumatology, and included 24 articles. This study highlights the growth of clinical pharmacy activities in rheumatology and the positive influence of clinical pharmacists on patient care. The implementation of such initiatives has the potential to improve medication adherence, reduce medication-related risks, and optimize associated healthcare costs. All these pharmaceutical interventions aim to make the patient care journey smoother and safer. Additionally, the diversity of available pharmaceutical services caters to the varied needs of rheumatology. Furthermore, outpatient clinical pharmacy is also explored in this field and garners interest from patients. The vast majority of studies demonstrate significant improvement in patient care with promising performance outcomes when pharmacists are involved. This review highlights the diverse range of interventions by clinical pharmacists in rheumatology, which is very promising. However, to better assess the benefits of clinical pharmacists, this activity needs further development and evaluation through controlled and randomized clinical research programs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Can efficacy and safety data from clinical trials of rituximab in RA be extrapolated? Insights from 1984 patients from the AIR-PR Registry.

Author

Nguyen, Yann, Mariette, Xavier, Gottenberg, Jacques E, Iudici, Michele, Morel, Jacques, Vittecoq, Olivier, Constantin, Arnaud, Flipo, Rene-Marc, Schaeverbeke, Thierry, Sibilia, Jean, Ravaud, Philippe, Porcher, Raphaël, and Seror, Raphaèle

Subjects
PATIENT safety, DRUG side effects, RHEUMATOID arthritis, CLINICAL trials, AUTOANTIBODIES, RITUXIMAB, TREATMENT effectiveness, ANTIRHEUMATIC agents, LONGITUDINAL method, RESEARCH, CONFIDENCE intervals, C-reactive protein
Abstract

Objectives To investigate whether the efficacy and safety data from drug-registration trials can be extrapolated to real-life RA patients receiving RTX. Methods The 'AutoImmunity and Rituximab' (AIR-PR) registry is a French multicentre, prospective cohort of RA patients treated with RTX in a real-life setting. We compared treatment responses at 12 months and serious adverse events (AEs) between eligible and non-eligible patients, by retrieving the eligibility criteria of the three rituximab-registration trials. We determined critical eligibility criteria and modelled the benefit–risk ratio according to the number of fulfilled critical eligibility criteria. Results Among 1984 RA patients, only 9–12% fulfilled all eligibility criteria. Non-eligible patients had fewer EULAR responses at 12 months (40.3% vs 46.9%, P  = 0.044). Critical inclusion criteria included swollen joints count ≥4, tender joints count ≥4, CRP ≥15 mg/l and RF positivity. Critical exclusion criteria were age >80 years, RA-associated systemic diseases, ACR functional class IV, DMARD other than MTX and prednisone >10 mg/day. Only 20.8% fulfilled those critical eligibility criteria. During the first year, serious AEs occurred for 182 (9.2%) patients (70.3% serious infections) and patients with ≥1 critical exclusion criterion were at higher risk (hazard ratio 3.03; 95% CI 2.25–4.06; for ≥3 criteria vs 0). The incremental risk–benefit ratio decreased with the number of unmet critical inclusion criteria and of fulfilled exclusion criteria. Conclusion Few real-life RA patients were eligible for the drug-registration trials. Non-eligible patients had lower chance of response, and higher risk of serious AEs. Efficacy and safety data obtained from those trials may not be generalizable to RA patients receiving RTX in real-world clinical practice. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Epidemiology of cutaneous involvement in Sjögren syndrome: Data from three French pSS populations (TEARS, ASSESS, diapSS)

Author

Villon, Camille, Orgeolet, Laure, Roguedas, Anne-Marie, Misery, Laurent, Gottenberg, Jacques-Eric, Cornec, Divi, Jousse-Joulin, Sandrine, Seror, Raphaele, Berthelot, Jean-Marie, Dieude, Philippe, Dubost, Jean-Jacques, Fauchais, Anne-Laure, Goeb, Vincent, Hachulla, Eric, Hatron, Pierre-Yves, Larroche, Claire, Hayem, Gilles, Le Guern, Véronique, Perdriger, Aleth, Morel, Jacques, Vittecoq, Olivier, Mariette, Xavier, Devauchelle-Pensec, Valérie, and Saraux, Alain

Published
2021
Full Text
View/download PDF

13. Repurposing the Fibrosis-4 Score in Rheumatoid Arthritis: Data from the ESPOIR Cohort.

Author

Felten, Renaud, Fabacher, Thibaut, Sedmak, Nathanaël, Sibilia, Jean, Sordet, Christelle, Chatelus, Emmanuel, Berenbaum, Francis, Combe, Bernard, Ruyssen-Witrand, Adeline, Vittecoq, Olivier, Meyer, Nicolas, and Gottenberg, Jacques-Eric

Subjects
RHEUMATOID arthritis, MAJOR adverse cardiovascular events, RANDOM effects model, ASPARTATE aminotransferase, ALANINE aminotransferase
Abstract

Background: We aimed to evaluate the value of the Fibrosis-4 (FIB-4) score as a prognostic factor in RA in the prospective ESPOIR cohort. Methods: We included patients from the ESPOIR cohort with a diagnosis of RA according to ACR/EULAR criteria. The formula for the FIB-4 score is as follows: [age (years) × aspartate transaminase level (U/L)]/[platelet count (109/L) × alanine aminotransferase level (U/L)1/2]. We used a linear mixed-effects model with a random effect of patient to account for repeated measures over time. Results: Overall, 647 of the 813 patients included met the ACR/EULAR criteria for RA, with no differential diagnosis during the first 10 years of follow-up. Of these patients, at baseline, 633 had a calculable FIB-4 score. Median FIB-4 score was 0.75 (interquartile range 0.53–0.99). On multivariate analysis, FIB-4 score was not independently associated with progression of Disease Activity Score in 28 joints over 10 years of follow-up, unlike baseline C-reactive protein level and SJC. Baseline FIB-4 score was not associated with the modified Sharp score at 5-year follow-up, unlike age and ACPAs. FIB-4 score was not associated with mortality (hazard ratio 1.1 [95% CI 0.46; 2.8], p = 0.77) or major adverse cardiovascular events (0.46 [0.13; 1.6], p = 0.22) over the 10-year follow-up. No significant change in FIB-4 score over time was related to treatments. Conclusions: The present prospective cohort study did not find a prognostic role of FIB-4 score in RA. Reassuringly, FIB-4 score was not increased with DMARD treatment after 10 years of follow-up. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials

Author

Devauchelle-Pensec, Valerie, Dieude, Philippe, Dubost, Jean Jacques, Fauchais, Anne-Laure, Goeb, Vincent, Hachulla, Eric, Larroche, Claire, Le Guern, Véronique, Morel, Jacques, Perdriger, Aleth, Puéchal, Xavier, Rist, Stephanie, Sen, Damien, Sibilia, Jean, Vittecoq, Olivier, Benessiano, Joelle, Tubiana, Sarah, Inamo, Karine, Gaete, Stanie, Batouche, Djilali, Molinari, Domitille, Randrianandrasana, Mickael, Pane, Isabelle, Abbe, Adeline, Baron, Gabriel, Ravaud, Philippe, Gottenberg, Jacques-Eric, Saraux, Alain, Devauchelle-Pensec, Valérie, Hayem, Gilles, Hatron, Pierre, Sene, Damien, Zarnitsky, Charles, Furlan, Valérie, Perrodeau, Elodie, Seror, Raphaele, Mariette, Xavier, Brown, S, Navarro, N Coy, Pitzalis, C, Emery, P, Pavitt, S, Gray, J, Hulme, C, Hall, F, Busch, R, Smith, P, Dawson, L, Bombardieri, M, Ng, W-F, Pease, C, Price, E, Sutcliffe, N, Woods, C, Ruddock, S, Everett, C, Reynolds, C, Skinner, E, Poveda-Gallego, A, Rout, J, Macleod, I, Rauz, S, Bowman, S, Ng, Wan-Fai, Bowman, Simon J, Griffiths, Bridget, Hall, Frances, Bacaba, Elalaine C, Frankland, Helen, Moots, Robert, Chadravarty, Kuntal, Lamabadusuriya, Shamin, Bombardieri, Michele, Pitzalis, Constantino, Sutcliffe, Nurhan, Breston, Celia, Gendi, Nagui, Culfear, Karen, Riddell, Claire, Hamburger, John, Richards, Andrea, Rauz, Saaeh, Brailsford, Sue, Dasgin, Joanne, Logan, Joanne, Mulherin, Diarmuid, Andrews, Jacqueline, Emery, Pau, McManus, Alison, Pease, Colin, Pickles, David, Booth, Alison, Regan, Marian, Kin, Jon King, Holt, Amanda, Dimitroulas, Theodoros, Kadiki, Lucy, Kaur, Daljit, Kitas, George, Khan, Abdul, Cosier, Tracey, Panthakalam, Mintrim, Kell, Lloyd, Mark, Moore, Lisa, Gordon, Esther, Lawson, Cathy, Gupta, Monica, Hunter, John, Stirton, Lesley, Ortiz, Gill, Price, Elizabeth, Pelger, Suzannah, Gorman, Claire, Hans, Balinder, Clunie, Gavin, Lane, Suzanne, Rose, Ginny, Cuckow, Sue, Batley, Michael, Einosas, Ruby, Knight, Susan, Symmons, Deborah, Jones, Beverley, Carr, Andrew, Edgar, Suzanne, Figuereido, Francisco, Foggo, Heather, Lendrem, Dennis, Macleod, Iain, Mitchell, Sheryl, Downie, Christine, Tarn, Jessica, Locke, James, Al-Ali, Shereen, Legg, Sarah, Mirza, Kamran, Hargreaves, Ben, Hetherington, Laura, Jones, Adrian, Lanyon, Peter, Muir, Alice, White, Paula, Young-Min, Steven, Pugmire, Susan, Vadivelu, Saravanan, Cooper, Annie, Watkins, Marianne, Field, Anne, Kaye, Stephen, Mewar, Devesh, Medcalf, Patricia, Tomlinson, Pamela, Whiteside, Debbie, McHugh, Neil, Pauling, John, James, Julie, Dowden, Andrea, Akil, Mohammed, McDermott, Jayne, Godia, Olivia, Coady, David, Kidd, Elizabeth, Palmer, Lynne, Li, Charles, Bartrum, Sarah, Mead, De, Dasgupta, Bhaskar, Katsande, Victoria, Long, Pamela, Vermaak, Erin, Turner, Janet, Chandra, Usha, MacKay, Kirsten, Fedele, Stefano, Ferenkeh-Koroma, Ada, Giles, Ian, Isenberg, David, MaConnell, Helena, Ahwiren, Nyarko, Porter, Stephen, Allcoa, Paul, McLaren, John, Tarn, Jessica R, Howard-Tripp, Nadia, Lendrem, Dennis W, Skelton, Andrew J, James, Katherine, McMeekin, Peter, Hackett, Katie L, Lendrem, B Clare, Casement, John, Pease, Colin T, Emery, Paul, Pitzalis, Costantino, Saravanan, Vadivelu, Johnsen, Svein J A, Norheim, Katrine B, Omdal, Roald, Stocken, Deborah, Everett, Colin, Fernandez, Catherine, and Isaacs, John D

Published
2019
Full Text
View/download PDF

21. Characterisation of airway disease associated with Sjögren disease.

Author

Meudec, Loïc, Debray, Marie-Pierre, Beurnier, Antoine, Marques, Cindy, Juge, Pierre-Antoine, Dhote, Robin, Larroche, Claire, Fauchais, Anne Laure, Dernis, Emanuelle, Vittecoq, Olivier, Saraux, Alain, Jacques-Eric, Jacques-Eric, Hachulla, Eric, Le Guern, Véronique, Dieudé, Philippe, Seror, Raphaele, Mariette, Xavier, and Nocturne, Gaétane

Published
2024
Full Text
View/download PDF

31. Biologic targeted therapies in pediatric rheumatology

Author

Guillaume-Czitrom, Séverine, Bachelez, Hervé, Berthelot, Jean-Marie, Bouhnik, Yoram, Bruckert, Eric, Claudepierre, Pascal, Constantin, Arnaud, de Bandt, Michel, Fautrel, Bruno, Gaudin, Philippe, Goëb, Vincent, Gossec, Laure, Gottenberg, Jacques-Eric, Goupille, Philippe, Hachulla, Eric, Huet, Isabelle, Jullien, Denis, Launay, Odile, Lemannf, Marc, Lequerré, Thierry, Maillefert, Jean-Francis, Mariette, Xavier, Marolleau, Jean-Pierre, Martinez, Valérie, Masson, Charles, Morel, Jacques, Mouthon, Luc, Pham, Thao, Pol, Stanislas, Puéchal, Xavier, Richette, Pascal, Saraux, Alain, Schaeverbeke, Thierry, Sellam, Jérémie, Blacher, Jacques, Soubrier, Martin, Sudre, Anne, Viguier, Manuelle, Vittecoq, Olivier, Wendling, Daniel, and Sibilia, Jean

Published
2014
Full Text
View/download PDF

38. Synovium CD20 expression is a potential new predictor of bone erosion progression in very-early arthritis treated by sequential DMARDs monotherapy – A pilot study from the VErA cohort

Author

Lanfant-Weybel, Karine, Michot, Chantal, Daveau, Romain, Milliez, Pierre-Yves, Auquit-Auckbur, Isabelle, Fardellone, Patrice, Brazier, Michel, Mejjad, Othmane, Daragon, Alain, Krzanowska, Kataryna, Jouen, Fabienne, Tron, François, Le Loarer, François, Le Loët, Xavier, and Vittecoq, Olivier

Published
2012
Full Text
View/download PDF

40. L’expression synoviale de CD20 représente un nouveau facteur prédictif potentiel de la progression des érosions osseuses lors d’une arthrite très récente traitée par DMARD en monothérapie séquentielle – étude pilote à partir de la cohorte VErA

Author

Lanfant-Weybel, Karine, Michot, Chantal, Daveau, Romain, Milliez, Pierre-Yves, Auquit-Auckbur, Isabelle, Fardellone, Patrice, Brazier, Michel, Mejjad, Othmane, Daragon, Alain, Krzanowska, Kataryna, Jouen, Fabienne, Tron, François, Le Loarer, François, Le Loët, Xavier, and Vittecoq, Olivier

Published
2012
Full Text
View/download PDF

42. Abatacept therapy and safety management

Author

Pham, Thao, Bachelez, Hervé, Berthelot, Jean-Marie, Blacher, Jacques, Claudepierre, Pascal, Constantin, Arnaud, Fautrel, Bruno, Gaujoux-Viala, Cécile, Goëb, Vincent, Gossec, Laure, Goupille, Philippe, Guillaume-Czitrom, Séverine, Hachulla, Eric, Lequerré, Thierry, Marolleau, Jean-Pierre, Martinez, Valérie, Masson, Charles, Mouthon, Luc, Puéchal, Xavier, Richette, Pascal, Saraux, Alain, Schaeverbeke, Thierry, Soubrier, Martin, Viguier, Manuelle, Vittecoq, Olivier, Wendling, Daniel, Mariette, Xavier, and Sibilia, Jean

Published
2012
Full Text
View/download PDF

43. TNF alpha antagonist therapy and safety monitoring

Author

Pham, Thao, Bachelez, Hervé, Berthelot, Jean-Marie, Blacher, Jacques, Bouhnik, Yoram, Claudepierre, Pascal, Constantin, Arnaud, Fautrel, Bruno, Gaudin, Philippe, Goëb, Vincent, Gossec, Laure, Goupille, Philippe, Guillaume-Czitrom, Séverine, Hachulla, Eric, Huet, Isabelle, Jullien, Denis, Launay, Odile, Lemann, Marc, Maillefert, Jean-Francis, Marolleau, Jean-Pierre, Martinez, Valérie, Masson, Charles, Morel, Jacques, Mouthon, Luc, Pol, Stanislas, Puéchal, Xavier, Richette, Pascal, Saraux, Alain, Schaeverbeke, Thierry, Soubrier, Martin, Sudre, Anne, Tran, Tu-Anh, Viguier, Manuelle, Vittecoq, Olivier, Wendling, Daniel, Mariette, Xavier, and Sibilia, Jean

Published
2011
Full Text
View/download PDF

48. Defining disease activity states and clinically meaningful improvement in primary Sjögrenʼs syndrome with EULAR primary Sjögrenʼs syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)

Author

Seror, Raphaèle, Bootsma, Hendrika, Saraux, Alain, Bowman, Simon J, Theander, Elke, Brun, Johan G, Baron, Gabriel, Le Guern, Véronique, Devauchelle-Pensec, Valérie, Ramos-Casals, Manel, Valim, Valeria, Dörner, Thomas, Tzioufas, Athanasios, Gottenberg, Jacques-Eric, Solans Laqué, Roser, Mandl, Thomas, Hachulla, Eric, Sivils, Kathy L, Ng, Wan-Fai, Fauchais, Anne-Laure, Bombardieri, Stefano, Priori, Roberta, Bartoloni, Elena, Goeb, Vincent, Praprotnik, Sonja, Sumida, Takayuki, Nishiyama, Sumusu, Caporali, Roberto, Kruize, Aike A, Vollenweider, Cristina, Ravaud, Philippe, Meiners, Petra, Brito-Zerón, Pilar, Vitali, Claudio, Mariette, Xavier, Gerli, Roberto, Kallenberg, Cees, Brun, Johan G, De Vita, Salvatore, Devauchelle, Valerie, Gottenberg, Jacques Eric, Demoulins, Frederic, Montecucco, Carlomaurizio, Tomsic, Matija, Casals, Manel Ramos, Scofield, Hal, Valesini, Guido, Devauchelle, Valerie, Saraux, Alain, Dubost, Jean-Jacques, Fauchais, Anne-Laure, Sibilia, Jean, Hayem, Gilles, Hatron, Pierre- Yves, Larroche, Claire, Guern, Veronique Le, Puéchal, Xavier, Morel, Jacques, Pedriger, Aleth, Rist, Stephanie, Sene, Damien, and Vittecoq, Olivier

Published
2016
Full Text
View/download PDF

50. A Risk Score to Detect Subclinical Rheumatoid Arthritis–Associated Interstitial Lung Disease.

Author

Juge, Pierre‐Antoine, Granger, Benjamin, Debray, Marie‐Pierre, Ebstein, Esther, Louis‐Sidney, Fabienne, Kedra, Joanna, Doyle, Tracy J., Borie, Raphaël, Constantin, Arnaud, Combe, Bernard, Flipo, René‐Marc, Mariette, Xavier, Vittecoq, Olivier, Saraux, Alain, Carvajal‐Alegria, Guillermo, Sibilia, Jean, Berenbaum, Francis, Kannengiesser, Caroline, Boileau, Catherine, and Sparks, Jeffrey A.

Subjects
CONFIDENCE intervals, MULTIPLE regression analysis, INTERSTITIAL lung diseases, RISK assessment, RHEUMATOID arthritis, GENOTYPES, DISEASE prevalence, DESCRIPTIVE statistics, BLOOD sedimentation, COMPUTED tomography, ODDS ratio, RECEIVER operating characteristic curves, LONGITUDINAL method, DISEASE risk factors, DISEASE complications
Abstract

Objective: Patients at high risk of rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) would benefit from being identified before the onset of respiratory symptoms; this can be done by screening patients with the use of chest high‐resolution computed tomography (HRCT). Our objective was to develop and validate a risk score for patients who have subclinical RA‐ILD. Methods: Our study included a discovery population and a replication population from 2 prospective RA cohorts (ESPOIR and TRANSLATE2, respectively) without pulmonary symptoms who had received chest HRCT scans. All patients were genotyped for MUC5B rs35705950. After multiple logistic regression, a risk score based on independent risk factors for subclinical RA‐ILD was developed in the discovery population and tested for validation in the replication population. Results: The discovery population included 163 patients with RA, and the replication population included 89 patients with RA. The prevalence of subclinical RA‐ILD was 19.0% and 16.9%, respectively. In the discovery population, independent risk factors for subclinical RA‐ILD were presence of the MUC5B rs35705950 T allele (odds ratio [OR] 3.74 [95% confidence interval (95% CI) 1.37, 10.39]), male sex (OR 3.93 [95% CI 1.40, 11.39]), older age at RA onset (for each year, OR 1.10 [95% CI 1.04, 1.16]), and increased mean Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (for each unit, OR 2.03 [95% CI 1.24, 3.42]). We developed and validated a derived risk score with receiver operating characteristic areas under the curve of 0.82 (95% CI 0.70–0.94) for the discovery population and 0.78 (95% CI 0.65–0.92) for the replication population. Excluding MUC5B rs35705950 from the model provided a lower goodness of fit (likelihood ratio test, P = 0.01). Conclusion: We developed and validated a risk score that could help identify patients at high risk of subclinical RA‐ILD. Our findings support an important contribution of MUC5B rs35705950 to subclinical RA‐ILD risk. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results